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Increased step-to-step variability is a feature of gait in individuals with Parkinson’s disease 
(PD) and is associated with increased disease severity and reductions in balance and mobility. 
The Gait Variability Index (GVI) quantifies gait variability in spatiotemporal variables where 
a score ≥ 100 indicates a similar level of gait variability as the control group, and lower scores 
denote increased gait variability. The study aim was to explore mean GVI score and 
investigate construct validity of the index for individuals with mild to moderate PD. 100 (57 
males) subjects with idiopathic PD, Hoehn &Yahr 2 (n=44) and 3, and ≥ 60 years were 
included. Data on disease severity, dynamic balance, mobility and spatiotemporal gait 
parameters at self-selected speed (GAITRite) was collected.  The results showed a mean 
overall GVI: 97.5 (SD 11.7) and mean GVI for the most affected side: 94.5 (SD 10.6). The 
associations between the GVI and Mini- BESTest and TUG were low (r = 0.33 and 0.42) and 
the GVI could not distinguish between Hoehn &Yahr 2 and 3 (AUC = 0.529, SE=0.058, 
p=0.622). The mean GVI was similar to previously reported values for older adults, contrary 
to consistent reports of increased gait variability in PD compared to healthy peers. Therefore, 
the validity of the GVI could not be confirmed for individuals with mild to moderate PD in its 
current form due to low associations with validated tests for functional balance and mobility 
and poor discriminatory ability. Future work should aim to establish which spatiotemporal 
variables are most informative regarding gait variability in individuals with PD. 
 




1. Introduction  
 
Parkinson’s disease (PD) is a neurodegenerative disorder with common features such as 
hypokinesia, resting tremor, rigidity and postural instability [1]. Disturbances of gait are 
apparent in almost all cases of PD and become more pronounced as the disease progresses [2].  
 
A feature of gait in individuals with PD is a decreased ability to produce a steady gait rhythm, 
resulting in higher step-to-step variability during walking [3]. Increased variability, thought to 
reflect reduced motor control, has been demonstrated for multiple spatiotemporal variables 
(STVs) in individuals with PD when performing level ground walking, treadmill walking, 
walking backwards and walking while undertaking a cognitive task [4-6]. Increased gait 
variability has been identified in newly diagnosed individuals [7] and was found to increase 
with disease severity [8]. Further, declining balance and mobility were associated with 
increased gait variability, which also has been shown to distinguish fallers from non-fallers 
[9, 10].  
 
However, when identifying gait variability it is unclear which single variable, or combination 
of several STVs, are most informative for any given neurological diagnosis or disease severity 
[11]. The Gait Variability Index (GVI) was recently developed as a potential standardized tool 
for quantifying gait variability in STVs [12]. The GVI was intended to be generic and 
therefore applicable to different diagnostic groups and disease severities. It was constructed as 
a conglomerate measure of nine weighted STVs seen in relation to a reference population. A 
GVI ≥ 100 indicates a similar level of gait variability as the reference population, and each 10 
point reduction in the score corresponds to one standard deviation from the reference mean 
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where lower scores denote increased gait variability. The GVI has previously been validated 
for individuals with Friedrich’s Ataxia [13] and for healthy elderly [13]. 
 
The study aim was to explore mean GVI score and investigate construct validity of the index 
for individuals with mild to moderate PD. To do so, the association between the GVI score 
and scores on dynamic balance and mobility tests was examined. A moderate to high 
correlation was postulated to signify that functional balance and mobility does not entirely 
reflect the same construct as gait variability, though closely related. Further, the 
discriminatory ability of the GVI was evaluated by investigating how well the index 
distinguishes mild from moderate disease severity. It was hypothesized that individuals with 





2.1 Participants  
 
Data for this cross sectional study was extracted from a larger randomized control trial (trial 
number: NCT01417598) [14]. 100 individuals (57 males) with mild to moderate PD were 
included based on the following criteria; having a clinical diagnosis of idiopathic PD 
according to the UK Parkinson’s Disease Society Brain Bank criteria [15], be in Hohen & 
Yahr (H&Y) stage 2 (n=44) or 3 (n=56) which is characterized by bilateral or midline 
involvement of symptoms, with (H&Y 3) or without (H&Y 2) postural instability [16], and be 
60 years or older. Participants were excluded if they had a history suggesting atypical PD 
symptoms as defined by Hughes et al [15], a Mini-Mental State Examination (MMSE) score ≤ 
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24 [17], or other existing neuromuscular disorders or medical conditions that influenced their 
gait and balance performance. Recruitment was done via advertisements in local newspapers, 
from Karolinska University Hospital and outpatient neurological clinics in Stockholm 
County, Sweden. Ethical approval was given by the Regional board of ethics in Stockholm, 
and all participants gave their informed consent.  
 
2.2 Control group 
 
The already existing control group values embedded in the GVI and made available by 
Gouelle et al. [12] was used. This control group represents normative variability values for 
matured adult gait and not age matched older adults. However, adding to, or replacing, these 
reference values would change the basis for the estimated mean gait variability representing a 
GVI of 100 and the following GVI calculations. This would make direct comparison with 
previously published GVI estimates invalid. Additionally, it was considered important to 
evaluate the index in its current form from a clinical application point of view. The control 
group gait variability values are presented in the supplementary excel macro file supplied by 
Gouelle et al [13] and displayed as 18 absolute difference values (vn) in percentage points for 
each control (see section 2.4). 
 
2.3 Procedures  
 
Participants used their regular medication during the study and those with motor fluctuations 
were tested in their medication “on” phase. Subjects were interviewed regarding their current 
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health status and general activity level, before their UPDRS motor examination score and 
H&Y score were determined. Following this, participants were instructed to walk back and 
forth on a pressure sensor mat (GAITRite, CIR Systems Inc., Franklin, NJ, USA). Balance 
was tested with the Mini Balance Evaluation Systems Test (Mini-BESTest) [18] and mobility 
with the Timed Up and Go (TUG) [19]. This was done in a randomized order.  
 
Spatiotemporal gait variables were collected on a GAITRite mat (active zone 8.3 meters) at 
their self-selected walking speed. To facilitate a steady pace, a distance of 2.5 meters was 
available on each side of the mat for acceleration and deceleration. The possibility of resting 
was given between walks. Up to six valid trials for each subject were included in the analysis.  
 
The Mini-BESTest is a 14 item test that focuses on dynamic balance, specifically anticipatory 
postural adjustments, postural responses, sensory orientation and dynamic gait. Each item is 
scored from 0-2 (0=unable, 2=normal) [18], with a maximum score of 28 points [20].  
 
Testing general mobility the TUG requires the subject to  rise from an arm chair, walk 3 
meters, turn, walk back, and sit down again at his or hers self-selected speed, while being 
timed. The subject wears shoes and uses his or hers walking aid [19]. Participants made a 
practice run prior to testing, and one valid attempt of the TUG was recorded.  
 
2.4 GVI calculations 
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The calculations were based on nine specified STVs (Table 3). These were generated using 
the GAITRite software (version 4.7). The GVI scores were calculated using the Excel macro 
(Excel®, Microsoft, USA) which is available as supplemental material provided by Gouelle et 
al [12].  
 
For any given STV i, within any given trial j (𝑆𝑇𝑉𝑖𝑗) the left and right foot falls were 
considered separately. The 𝑆𝑇𝑉𝑖𝑗 trial mean was given the dimensionless value of 100 
percent, and the intra trial 𝑆𝑇𝑉𝑖𝑗 foot falls were expressed in percentage points in relation to 
its trial mean. The percentage point difference between foot falls within a trial were calculated 
over all trials, giving an absolute difference mean and SD of 𝑆𝑇𝑉𝑖 foot falls. The mean 
evaluates the magnitude of the variability and the SD provides an additional measure of its 
consistency [12]. This procedure gave 18 alternative variables (𝑣𝑛) for each lower limb. These 
were adjusted in relation to weighting coefficients 𝑐𝑛 determined by Gouelle et al [12] 
through a principal component analysis, and for a subject (𝛼) the sum of the products was 
calculated: 
 





The distance between a subject sum score and the mean sum score of the control group (𝜎) 
was determined: 
  
𝑑𝛼,𝜎 = ‖𝑠𝛼 − 𝑠𝜎‖                                                                                                                                   (2) 
 





𝛼 = 𝑙𝑛(𝑑𝛼,𝜎)                                                                                                                                (3) 
 









                                                                                                         (4)  
 
The z-score was used to determine the GVI score as follows: 
 
𝐺𝑉𝐼𝛼 = 100 − 10 𝑥 𝑧𝐺𝑉𝐼𝑟𝑎𝑤
𝛼                                                                                                                              (5) 
 
The overall GVI is the mean of right and left side.  
 
2.5 Statistical analysis 
 
To explore the variability in the raw spatiotemporal variables used in the GVI the within-
subject SD was calculated based on < 30 steps. Also, the extracted 18 absolute difference 
values for the control group was compared to the equivalent values from the PD cohort to 
further evaluate to what extent the groups differed. Despite bilateral involvement of 
symptoms in H&Y stage 2 and 3, there is in most cases substantial asymmetry of clinical 
symptoms from disease onset [21]. Therefore both the overall GVI and the GVI score for the 
most affected side (mean, SD) were calculated both for the total group and for the sub-groups 
H&Y 2 and 3. Independent samples t-test and Cohen’s d effects size was used to investigate 
significance and magnitude of differences between the PD cohort and control group, and 
further for sub-groups H&Y 2 and 3. Paired samples t-test was used to determine if there was 
a significant difference between the overall and most affected side GVI scores. The following 
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categorization was used to interpret the Cohn’s d effect sizes (ES): small=0.2; medium =0.5; 
and large =0.8 [22]. The Pearson’s correlation coefficient was used to investigate the 
association between GVI and the Mini-BESTest and the TUG. Due to a heteroscedastic 
distribution in the data, an inverse transformation was performed on the TUG scores (1/TUG).  
The strength of all correlations where interpreted according to Munro (p. 358 [23]); <0.25= 
little if any correlation; 0.25=low correlation; 0.50= moderate correlation; 0.70=high 
correlation; 0.90=very high correlation. The discriminatory ability of the GVI, with regards to 
the ability to distinguish between H&Y 2 and 3, was investigated using ROC curve analysis. 
The strength of discrimination was interpreted according to Hosmer and Lemeshow (p. 473 
[24]); 0.5=no discrimination; 0.7=acceptable; 0.8=excellent; 0.9=outstanding. Significance 




Demographic description of the participants is shown in Table 1. The within-person SD for 
the 9 raw spatiotemporal variables is shown in Table 2. 
 
3.1 Comparing the PD cohort to the control group 
 
The 18 absolute difference values in percentage points for the PD cohort and the control 
group are shown in Table 3. The PD cohort showed higher gait variability in 15 of the 18 
variables and 14 of the 18 were significantly different. In 7 of the variables these differences 
were considered large (ES>0.8). The largest differences were seen in step length, swing time 
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and single support time where individuals with PD had approximately 1.5 percentage points 
larger mean gait variability compared to controls (p<0.01, ES=0.93-1.19). 
 
3.2 GVI values for individuals with PD 
 
The mean overall GVI was 97.5 (SD 11.7) and 94.5 (SD 10.6) for the most affected side. This 
is significantly different from the reported reference group mean of 100.3 (SD 7.6) [12] for 
both overall GVI (mean difference: 2.8, 95% CI [0.2-5.4],  p= 0.04) and most affected side 
(mean difference: 5.8, 95% CI [3.4-8.2], p<0.001). Further, the GVI of the most affected side 
was significantly lower as compared to the overall GVI (mean difference: 3.0, 95% CI [2.4- 
3.5], p< 0.001).  
 
3.3 Associations between GVI and dynamic balance and mobility 
 
A low correlation was found between the Mini-BESTest and GVI (overall GVI: r= 0.33, 
p<0.001; GVI most affected side: r= 0.29, p=0.004) as well as between the 1/TUG and GVI 
(overall GVI: r= 0.42, p< 0.001, GVI most affected side: r= 0.42, p< 0.001) (Figure 1).  
 
3.4 Ability of the GVI to discriminate mild from moderate disease severity in PD 
 
The within-person SD for H&Y 2 and 3 showed that there were significant differences in 
variability between the sub-groups in 4 out of the 9 raw STVs used in the GVI, and two 
additional variables were close to significance (SD swing time and SD double support time). 
However, there was no significant difference between the mean GVI for H&Y 2 and 3, either 
for the overall GVI (mean difference: -0.9, p=0.6) or the most affected side (mean difference: 
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-0.9, p=0.6) (Table 2). Further, the ROC curve analysis showed low discriminatory ability 
both for overall GVI (AUC = 0.529, SE=0.058, p=0.622) and GVI most affected side (AUC = 




The main finding of this study was that the mean GVI in a population of individuals with mild 
to moderate PD was close to normal (97.5), indicating only a small increase in gait variability, 
even when only considering the most affected side (94.5). Further, the GVI scores correlated 
poorly with dynamic balance and mobility scores, and lastly, the index showed poor ability in 
discriminating mild from moderate disease severity with no significant difference in the GVI 
between groups.  
 
 
Despite the GVIs being significantly lower than the control group mean of 100.3, both scores 
were within ½ SD, indicating only a small increase in gait variability for this group. Also, the 
GVIs found in this study were slightly higher, or equal too, previously reported GVIs for 
elderly people, where the mean overall GVI was 91.9, ranging from 89.3 to 94.3 in healthy 
older adults, and 96.4 for high functioning older adults [13]. This suggests that gait variability 
in individuals with PD in these stages is comparable to healthy peers. As no other study to our 
knowledge has investigated GVI values in the PD population, we deemed it reasonable to 
view our results in relation to other reports on gait variability in separate STVs for individuals 
with PD. Other investigations show higher gait variability in mild to moderate PD compared 
to healthy controls, such as for stride time, stride length, step time, swing time, double support 
time and stride velocity [4, 8, 25, 26]. These are all variables included in the GVI, and 
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importantly, the levels of gait variability reported in these studies are similar to those found in 
our results (Table 2). Additionally, when comparing the gait variability in the PD cohort 
against the control group, the PD cohort showed significantly higher variability in 14 of the 
18 variables that go into the GVI calculations, and in 7 of the variables these differences were 
deemed large (ES>0.8) (Table 3). One must therefore consider that the reported increase in 
gait variability in separate STVs for individuals with PD was not reflected in the sum score of 
the GVI, leading to the contradictory results of equal, or even higher, GVI scores in 
individuals with PD compared to those reported for healthy older adults.  
 
Previous studies have shown associations between increased gait variability in individual 
STVs and reduced balance and mobility [9, 10, 27, 28]. Also, higher gait variability has been 
found in those with moderate compared to mild PD severity [8, 29]. These findings were not 
verified by our results where the index scores showed low correlation with dynamic balance 
and mobility scores, and further, poor ability to distinguish the moderate from the mild cases. 
Interestingly, the discriminatory ability of the GVI has been demonstrated for other groups, 
such as level of Friedrich’s Ataxia classified by the International Cooperative Ataxia Rating 
Scale [12], and higher functioning older adults as opposed to those with reduced mobility 
[13]. Certainly, the mean GVI differences were more distinct in these groups compared to 
those found for H&Y 2 and 3 in this study, suggesting that the GVI performs better in these 
diagnostic groups as opposed to PD. On the other hand, a previous report utilizing a similar 
cohort as this study, showed that the Mini-BESTest had acceptable ability to distinguish H&Y 
2 from 3 [30]. The argument can be made that the GVI was not sensitive enough to detect 
known group differences in individuals with PD, a difference which has been detected by a 
validated dynamic balance test. This, together with the fact that the mean values of the GVI in 
this cohort were equal to those of healthy peers, and the low correlation found between the 
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GVI and dynamic balance and mobility scores, we consider the GVI to exhibit poor construct 
validity for individuals with PD. 
 
There may be several reasons for why the GVI does not reflect the expected gait variability in 
individuals with PD. Firstly, as many as 44 % of the cohort had GVI values of 100 or above 
for the overall GVI, and 28 % for the most affected side. All values over 100 are regarded as 
normal levels of gait variability [12, 13] regardless if the GVI is 101 or 130. The reason for 
these higher values is seen in equation 3. When the difference between the subject and control 
group is small the natural log of values approaching zero will tend toward infinity resulting in 
an exponential distribution in GVI values well above 100. Although there is no 
interpretational difference between a GVI of 101 or 130, it is clear that the more extreme 
values will elevate the group mean and give a misleading result. It was therefore appealing to 
explore median GVI when all values over 100 were scored as 100. This resulted in little 
change from the initial group mean GVIs, where the median overall GVI was 97.9 and the 
median GVI most affected side was 95.2.   
 
Secondly, higher values can also result in masking of unilateral increase in gait variability in 
the overall GVI calculation. If one side has normal gait variability with a GVI of 120, whereas 
the most affected side has an increased variability with a GVI of 80, this would give an 
overall GVI of 100 and wrongly be assessed as normal. The reduction in values of 100 or 
higher from 44% for overall GVI to 28% for most affected side indicates that a unilateral 
increase in gait variability has been equaled out by the closer to normal contralateral side. 




Thirdly, the GVI has an exponential distribution rather than a linear one, inferring that 
changes in GVI scores relative to the underlying gait variability is not evenly distributed 
across the continuum of the index. Individuals with a high GVI could see relatively large 
changes in the score with only small changes in variability, whereas in those with low GVI, 
the same changes in gait variability would show minimal changes in the GVI score. This 
implies that using the index to monitor change over time in an individual or group, or 
comparing different groups, is problematic both clinically and statistically.  
 
Lastly, the seemingly low sensitivity of the GVI to display increased gait variability in 
individuals with PD, and further distinguish between mild and moderate disease severity, may 
reflect the inclusion of multiple STVs. Considering the differences found in the gait 
variability in the PD cohort compared to the control group (Table 3), could indicate that key 
variables becomes leveled out by those less important, leading to an under-representation in 
the GVI sum score. There is to date no consensus in the literature which STVs best represent 
gait variability in individuals with PD, though swing time has been reported to display the 
highest CV value differences from healthy peers in multiple studies of approximately 1.5 
percentage points, [4, 7, 26, 31] and is supported by our results where step length, swing time 
and  single support time showed the largest differences from the control group. It is important 
to note that single support time and swing time are highly correlated due to the combined 
values for the left and right side. The two events happen simultaneously but on opposite legs 
interchangeably, and the norm is to report one of the two variables. Conversely, Lord et al 
[11] identified in their gait model a cluster of STVs found to be most informative of 
variability in the gait of individuals with PD. These were step and stance time variability, step 
length and step velocity variability. However, with regards to the GVI it could be argued that 
the weighting coefficients used in the calculation ensures that the variability for each 
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parameter is appropriately expressed in the total summation. However, one must consider that 
these weights were based on combined data from healthy individuals and varied pathologies, 
and therefore question if the coefficients are representative for other groups such as 
individuals with PD. The model proposed by Lord et al [11] is perhaps one way forward, 
where clusters of variables that explain most of the underlying construct of gait variability are 




It is important to highlight that the control group used was not collected as part of this study 
and represent variability found in matured adult gait, rather than gait variability in age 
matched older adults. Also, potential differences in testing protocols between the two studies 
could have influenced our results. The control group data was collected at two different sites 
using slightly shorter GAITRite mats than the one used in this study. However, similar 
distances were used before and after the mat to ensure steady state walking, and similar 
amount of steps were analysed in this study as was done by Gouelle et al [12] making it 
unlikely that  that these differences have influenced the result to a large extent.  
 
Further, our results are only applicable to gait variability measured for individuals with PD in 
their medication “on” phase. Literature indicates that improvements in straight walking as a 
result of dopaminergic treatment are mainly seen in spatial parameters such as stride/ step 
length and is related to improvements of bradykinesia. However, temporal variables and gait 
variability does not appear to be improved significantly by levodopa [32]. As the majority of 
the variables included in the GVI are temporal, the argument can be made that testing the 
participants in the “on” phase would not have influenced our results greatly. However, 
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contradicting this, Bryant et al. [25] showed improved variability in step time, swing time, 
stride length and stride velocity when investigating the effects of levodopa on gait in 
Parkinson’s disease. It seems that further research is warranted to investigate these 
contradictory results, and our results should be interpreted accordingly.  
 
Conclusion 
The mean GVI scores for individuals with mild to moderate PD were found to be relatively 
high, within ½ SD of the reference population mean, and similar to reported GVI values for 
older adults. This is contrary to consistent accounts of increased gait variability in individuals 
with PD compared to healthy peers. The GVI displayed low correlation with validated tests 
for functional mobility and balance, and poor discriminatory ability in identifying level of 
disease severity. This was contrary to previous findings showing that increased gait variability 
was associated with disease severity and decreased balance and mobility capabilities. 
Therefore, the validity of the GVI could not be confirmed for individuals with mild to 
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Fig 1. The correlation between the Mini Balance Evaluation Systems Test and the Gait Variability Index (GVI), and the inverse transformed 
Timed Up and Go and the GVI. The association between GVI and dynamic balance were found to be low both for the overall GVI (A) and the 





Fig 2. The ability of the overall Gait Variability Index (GVI) (A) and the GVI most affected side (B) to distinguish mild from moderate disease 




Table 1  
Participant Characteristics (means and standard deviations). 
 PD cohort total  Hoehn & Yahr 2 Hoehn & Yahr 3 
Number of participants 100 44 56 
Sex (male/ female) 57/ 43 25/19 32/ 24 
Age (years) 73.2 (5.6) 72.7 (5.7) 73.5 (5.6) 
Height (cm) 171.0 (8.9) 172.0 (7.8) 170.0 (9,6) 
Body Mass Index (kg/m
2
) 22.0 (3.4) 22.0 (3.3) 21.8 (3.5) 
Years since diagnosis 5.8 (5.0) 4.0 (2.9) 7.0 (5.7) 
UPDRS subscale III (0-108 points) 36.6 (10.5) 34.4 (9.5) 38.5 (10.7) 
















SD Step length (cm) 2.48 2.52 2.46  0.66 
SD Stride length (cm) 3.82 3.86 3.79  0.78 
SD Step time (ms) 18.6 16.8 20.0  0.04* 
SD Stride time (ms) 26.8 23.9 29.1  0.03* 
SD Swing time (ms) 17.1 15.7 18.2  0.06 
SD Stance time (ms) 21.3 19.0 23.2  0.01* 
SD Single support time (ms) 16.9 14.9 18.4  0.01* 
SD Double support time (ms) 20.6 19.4 21.6  0.08 
SD Stride Velocity (cm/s) 4.67 4.56 4.74  0.53 
      
GVI overall 97.5 98.1 97.1  0.66 
GVI most affected side 94.5 95.1 94.1  0.67 
Abbreviations: SD=standard deviation; PD=Parkinson’s disease: H&Y=Hoehn and Yahr scale;  
GVI= gait variability index; *=significantly different.The calculations are for left side only and  







Table 3.  
Within-subject gait variability expressed as absolute difference values in percentage points (mean and SD) for the PD cohort and  
GVI control group (combined left and right side). 




















Step length 3.62 2.15 1.47 < 0.01* 1.19 2.92 1.72 1.20 < 0.01* 1.92 
Stride length 2.61 1.72 0.89 < 0.01* 0.99 2.06 1.27 0.79 < 0.01* 1.06 
Step time 3.23 2.73 0.50 < 0.01* 0.47 2.55 2.11 0.44 < 0.01* 0.50 
Stride time 2.26 1.94 0.32 < 0.01* 0.38 1.76 1.48 0.28  <0.01* 0.38 
Swing time 4.67 3.21 1.46 < 0.01* 0.93 3.58 2.52 1.06 < 0.01* 0.85 
Stance time 2.56 2.41 0.15  0.19 0.15 2.01 1.93 0.08  0.41 0.09 
Single sup. Time 4.68 3.04 1.54 < 0.01* 1.06 3.58 2.68 0.90 < 0.01* 0.70 
Double sup. Time 5.97 6.22 -0.25  0.30 0.13 4.54 5.40 -0.85 < 0.01* 0.44 
Stride velocity 2.59 2.87 -0.28  0.04* 0.27 2.00 1.86 0.14  0.13 0.18 
Abbreviations: SD = standard deviation; PD = Parkinson’s disease; GVI = Gait Variability Index; Var = variability; Diff = difference; sup = support.  
Effect size=Cohen’s d. The control group data is extracted from Gouelle et al (2013).  
 
 
 
 
 
